Early-onset group B strep: New guidance includes changes in dosing, assessment
Karen M.Puopolo, M.D., Ph.D., FAAP
AAP Clinical Report
The AAP has updated guidance for early-onset and late-onset group B streptococcal
(GBS) disease that includes several major changes to neonatal practice. The clinical
report and a separate update on maternal management from the American College of Obstetricians
and Gynecologists (ACOG) replace the consensus GBS prevention guidance published in
2010 by the Centers for Disease Control and Prevention (CDC).
The AAP clinical report Management of Infants at Risk for Group B Streptococcal Disease, from the Committee on Fetus and Newborn (COFN) and Committee on Infectious Diseases
(COID),is available at https://pediatrics.aappublications.org/content/early/2019/07/04/peds.2019-1881 and will be published in the August issue of Pediatrics. The AAP-endorsed ACOG Committee Opinion No. 782, Prevention of Group B Streptococcal Early-Onset Disease in Newborns, can be found at http://bit.ly/2Xka5OH (Obstet Gynecol. 2019;134:e19-e40).
GBS remains the most common single bacterial cause of neonatal early-onset sepsis.
The CDC first published consensus guidelines on the prevention of perinatal GBS disease
in 1996 in collaboration with the AAP, ACOG and other organizations.
The guidelines were updated in 2002 and 2010, recommending a universal antenatal culture-based
approach and administration of intrapartum antibiotic prophylaxis (IAP) to prevent
invasive neonatal GBS early-onset disease. With implementation of the approach, the
national incidence of GBS early-onset disease declined from 1.8 cases per 1,000 live
births in 1990 to 0.23 cases per 1,000 live births in 2015.
New data have emerged on the microbiology, epidemiology and clinical management of
perinatal GBS infection. In 2017, the CDC approached the AAP and ACOG with a proposal
to review and revise the 2010 GBS guidelines. CDC priorities required that the professional
organizations assume primary leadership for this review. Members of COFN and COID
collaborated with the ACOG Committee on Obstetric Practice to develop separate but
The AAP GBS clinical report, endorsed by ACOG, updates information on national GBS
microbiology and epidemiology, and recommendations for identification and management
of newborns at risk for this disease.
The CDC 2010 guidelines included a neonatal management algorithm for secondary prevention
of GBS early-onset disease that was widely adopted by neonatal physicians to manage
risk of all bacterial causes of early-onset sepsis. The revised GBS early-onset disease
guidance aligns with recently updated AAP management recommendations for all bacterial
causes of early-onset sepsis (http://bit.ly/2FX05Az, http://bit.ly/2FKlX1V).
In addition, the AAP GBS report provides updated recommendations for management of
GBS late-onset disease and for definitive treatment of GBS early- and late-onset disease.
Following are highlights of the AAP recommendations:
Risk assessment for early-onset GBS disease should follow the general principles established
in the AAP clinical reports on management of neonates with suspected or proven early-onset
bacterial sepsis. These principles include separate consideration of infants born
at ≥35 weeks’ gestation and those born at <35 weeks’ gestation.
For the purpose of neonatal management, the administration of intrapartum penicillin
G, ampicillin or cefazolin can provide adequate IAP against neonatal early-onset GBS
Clindamycin and vancomycin should be administered to women at high risk of anaphylaxis
to beta-lactam antibiotics as recommended by the ACOG. There is insufficient evidence
to consider these antibiotics to provide fully adequate IAP for the purpose of neonatal
Early-onset GBS infection is diagnosed by blood or cerebrospinal fluid culture. Laboratory
tests such as the complete blood cell count and C-reactive protein do not perform
well in predicting early-onset infection, particularly among those with low baseline
risk of infection.
Evaluation for late-onset GBS disease is based on clinical signs of illness in the
infant, and diagnosis is based on the isolation of group B streptococci from normally
sterile sites. Adequate IAP does not protect infants from late-onset GBS disease.
Empirical antibiotic therapy for early- and late-onset GBS disease differs by postnatal
age at the time of evaluation. Penicillin G is the preferred antibiotic for definitive
treatment of GBS disease in infants; ampicillin is an acceptable alternative.
Revised ACOG guidelines continue to endorse GBS prevention strategies based on universal
maternal antenatal vaginal-rectal culture-based screening and the use of IAP during
labor for GBS-colonized and other at-risk women.
Notable aspects of the guidance include the following:
The optimal window for antenatal GBS screening has been changed to 36 0/7 to 37 6/7
weeks’ gestation instead of beginning at 35 0/7 weeks’ gestation. The correlation
between antenatal GBS colonization results and colonization status at the time of
delivery decreases significantly when the culture-to-birth interval is longer than
five weeks; therefore, moving antenatal culture timing to 36-37 weeks optimizes the
value of the screening result up to 41 weeks’ gestation.
It is recommended that GBS IAP be administered to the following: all laboring women
with GBS colonization detected by antenatal culture; those with GBS bacteriuria detected
during the pregnancy; those who previously delivered a newborn with GBS disease; and
women with unknown GBS status who present with preterm labor or preterm, prelabor
rupture of membranes (ROM) prior to 37 weeks’ gestation.
Women who present at >37 weeks’ gestation with unknown status should be administered
GBS IAP if risk factors develop (duration of ROM ≥18 hours or intrapartum temperature
of ≥100.4°F [38°C]. Additionally, women with known GBS colonization in a prior pregnancy
may be offered IAP if status is unknown at >37 weeks’ gestation given that such women
have increased risk of colonization in the current pregnancy.
Penicillin G remains the recommended antibiotic for GBS IAP; ampicillin is an acceptable
alternative. For women with reported allergy to penicillin, recommendations are provided
for the use of cefazolin, clindamycin or vancomycin under certain circumstances depending
on the nature of the allergy and the antibiotic susceptibility of the colonizing GBS
Pregnant women with reported penicillin allergy are encouraged to seek formal allergy
testing because most women who have a reported penicillin allergy are, in fact, penicillin
Dr. Puopolo is a lead author of the clinical report and a member of the AAP Committee
on Fetus and Newborn.